Zhang Liyu, Buonfiglio Francesco, Fieß Achim, Pfeiffer Norbert, Gericke Adrian
Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany.
Antioxidants (Basel). 2024 Jan 25;13(2):148. doi: 10.3390/antiox13020148.
Retinopathy of prematurity (ROP) is a proliferative vascular ailment affecting the retina. It is the main risk factor for visual impairment and blindness in infants and young children worldwide. If left undiagnosed and untreated, it can progress to retinal detachment and severe visual impairment. Geographical variations in ROP epidemiology have emerged over recent decades, attributable to differing levels of care provided to preterm infants across countries and regions. Our understanding of the causes of ROP, screening, diagnosis, treatment, and associated risk factors continues to advance. This review article aims to present the pathophysiological mechanisms of ROP, including its treatment. Specifically, it delves into the latest cutting-edge treatment approaches targeting hypoxia and redox signaling pathways for this condition.
早产儿视网膜病变(ROP)是一种影响视网膜的增殖性血管疾病。它是全球婴幼儿视力损害和失明的主要危险因素。如果未被诊断和治疗,它可能会发展为视网膜脱离和严重的视力损害。近几十年来,ROP流行病学出现了地域差异,这归因于不同国家和地区对早产儿提供的护理水平不同。我们对ROP的病因、筛查、诊断、治疗及相关危险因素的理解不断进步。这篇综述文章旨在阐述ROP的病理生理机制,包括其治疗方法。具体而言,它深入探讨了针对这种疾病靶向缺氧和氧化还原信号通路的最新前沿治疗方法。